Aerogen

Aerogen is one of the world’s leading medical devices company, specializing in the design, manufacture, and commercialization of aerosol drug-delivery systems. Their patented vibrating-mesh technology turns liquid medication into a fine particle mist, gently and effectively delivering drugs to the lungs of critically ill patients of all ages. Their innovative products – Aerogen Solo and Aerogen Ultra – significantly improve aerosol drug delivery, resulting in better patient care throughout the hospital including ICU, HDU, ED, wards, neonate, and pediatric departments.

Founded in Galway, Ireland, in 1997, Aerogen have grown to become the global leader in high-performance aerosol-drug delivery and have partnered their technology with the world’s leading mechanical-ventilation companies.

In India, Aerogen has continued to expand its international activities through the opening of its Indian Commercial Headquarters in April 2019.
Headed by Rajiv Julka, country manager India, the Aerogen India team now has three sales managers and three clinical specialists located across the country, working with and supporting distributors.

The team is well experienced in the Indian critical-care sector and as such ensures that Aerogen continues to deliver superior customer support across the country.

John Power, Aerogen CEO and Founder, states, “India is an extremely important market for Aerogen, and we look forward to continuing to strengthen our commitment here. With an in-country office, and an experienced team we are working closely with our customers and partners to meet their individual needs and grow together.”

Aerogen offers a unique vibrating-mesh technology, available within the Aerogen Solo and Aerogen Pro, which has been adopted for use across many areas of the hospital during a variety of ventilatory support including conventional mechanical ventilation, high-frequency oscillatory ventilation, non-invasive ventilation, and high-flow nasal cannula. Clinical researchers have established its superior performance in bench and imaging studies. Aerogen devices can provide the patient with up to 9-fold higher drug dose than a standard small volume nebulizer (SVN) during mechanical ventilation. In pediatric patients, in respiratory failure Aerogen aerosolized Salbutamol resulted in improved lung recruitment.

The Aerogen technology is not only available for use during both invasive and non-invasive ventilation but can be used with spontaneously breathing patients with mouthpieces and masks throughout the acute care setting where Aerogen Ultra enables effective aerosol therapy of up to 35 percent inhaled dose available to the patient. Recent clinical data have shown significant improvements in clinical outcomes and reduced drug dose in the ED for all patients requiring Salbutamol via the Aerogen Ultra.